

## Publikační činnost Kliniky hematonekologie za rok 2019

### Publikace in extenso:

#### Články v časopisech s IF (158,102)

1. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, **Hajek R**, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2019 Jan 19;393(10168):253-264. IF 53,254
2. **Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R**. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14]. *Am J Hematol*. 2019 Jan;94(1):E35-E37 IF 5,303
3. Jurczynszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząsko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, **Hajek R**, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. *Leuk Lymphoma*. 2019 Jan;60(1):118-123. IF 2,644
4. Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, **Hájek R**, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. *MDM Policy Pract*. 2019 Jan 17;4(1):2381468318814253. IF 2,793
5. Steiner, N; **Hajek, R**; Nachbaur, D; Borjan, B; Sevcikova, S; Gobel, G; Gunsilius, E. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target? *DISEASE MARKERS* 2019;1806034. IF 2,949
6. Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, **Hajek R**, Feng S, Cocks K, Buchanan J, Weisel K. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. *Blood Cancer J*. 2019 Feb 22;9(3):23. IF 7,895
7. Jurczynszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, **Hajek R**, Robak P, Ražný M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. *Leuk Lymphoma*. 2019 Feb;60(2):471-476. IF 2,644
8. Radocha J, **Hájek R**, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, **Jelínek T**, Heindorfer A, Sýkora M, Maisnar V. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. *Ann Hematol*. 2019 Apr;98(4):951-962. IF 2,845

9. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, **Hajek R**, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*. 2019 May 2;133(18):1953-1963. IF 15,132
10. Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova M, Radocha J, Gregora E, Stecova N, **Jelinek T**, Jungova A, Kralikova E, Brozova L, **Hajek R**. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. *Neoplasma*. 2019 May 23;66(3):499-505. IF 1,771
11. **Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M**, Salounova D, **Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z**. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. *Bone Marrow Transplant*. 2019 Jul;54(7):1107-1111. IF 4,497
12. Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, **Hajek R**, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. *Leukemia*. 2019 Jul;33(7):1817-1821. IF 9,944
13. Sevcikova S, Minarik J, Stork M, **Jelinek T**, Pour L, **Hajek R**. Extramedullary disease in multiple myeloma - controversies and future directions. *Blood Rev*. 2019 Jul;36:32-39. IF 6,125
14. Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, **Jelinek T**, Brozova L, Krhovska P, Scudla V, **Hajek R**. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2019 Sep;163(3):279-283. IF 1,087
15. Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, **Hájek R**, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. *Ann Hematol*. 2019 Sep;98(9):2139-2150. IF 2,85
16. Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, **Hajek R**, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, **Jelinek T**, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. *Leuk Lymphoma*. 2019 Sep 26:1-10. IF 2,674
17. Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, **Duras J**, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. *Ann Hematol*. 2019 Aug;98(8):1961-1972. IF 2,85
18. Ludwig H, Pönisch W, Knop S, Egle A, Schreder M, Lechner D, **Hajek R**, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. *Br J Cancer*. 2019 Oct;121(9):751-757. IF 5,922

19. **Hájek R**, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. *Br J Haematol*. 2019 Nov;187(4):447-458 IF 5,67
20. Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibaldi O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, Spencer A, **Hájek R**, Boccadoro M, Gay F. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. *Cancers (Basel)*. 2019 Nov 5;11(11). pii: E1735. IF 6,162
21. **Hrdinka M**, Yabal M. Inhibitor of apoptosis proteins in human health and disease. *Genes Immun*. 2019 Nov;20(8):641-650. IF 2,339
22. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, **Hájek R**, Ludwig H, Facon T, San Miguel JF, Einsele H. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. *Haematologica*. 2019 Dec;104(12):2358-2360. IF 7,57
23. Kral, Z; Michalka, J; Mocikova, H; Markova, J; Sykorova, A; Belada, D; Jungova, A; Vokurka, S; Lukasova, M; Prochazka, V; **Duras, J; Hajek, R**; Dusek, L; Drgona, L; Ladicka, M; Ballova, V; Vranovsky, A. Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. *JOURNAL OF CANCER*, 10 (21):5041-5048. IF 3,182

#### Články v recenzovaných časopisech

1. Weinbergerová B, Kabut T, Kocmanová I, Drgoňa L, Kouba M, Hričinová M, Gabzdilová J, Guman T, Petečuková V, Novák J, Forsterová K, Haber J, Žiaková B, Bojtárová E, Zavřelová A, Karas M, Chrenková V, Sedláček P, Tkáčiková B, Múdry P, Mallátová N, Timr P, Kolenová A, Tanušková D, Horáková J, **Navrátil M**, Chudej J, Sokol J, Rolencová M, Žák P, Cetkovský P, Mayer J, Ráčil Z. Změny v epidemiologii invazivních mykotických infekcí v českých a slovenských hematologických centrech v letech 2005–2017: analýza dat FIND. *TRANSFUZE HEMATOL. DNES* 25, 2019 186-196
2. Pika T, **Hájek R**, et al. DIAGNOSTIKA A LÉČBA SYSTÉMOVÉ AL AMYLOIDÓZY. *Transfuze Hematol. dnes*,25, 2019, No. Supplementum 1, p. 37-71.
3. **Kašćák M**, **Hájek R**, Minařík J, **Jelínek T**, et al. DIAGNOSTIKA A LÉČBA WALDENSTRÖMOVY MAKROGLOBULINEMIE. *Transfuze Hematol. dnes*,25, 2019, No. Supplementum 1, p. 7-33.
4. **Hájek R**. Vývoj diagnostiky a léčby mnohočetného myelomu v průběhu posledních 25 let. *Transfuze a hematologie dnes*. 2019, roč. 25, č. 1, s. 96-106.

#### Články v ostatních časopisech

1. Butova R, Vychytilova-Faltesjkova P, Souckova A, Sevcikova S, **Hájek R**. Long Non-Coding RNAs in Multiple Myeloma. *Noncoding RNA*. 2019 Jan 24;5(1).
2. **Zuchnická J**, **Richterová P**, Rusiňáková Z, Faber E, **Hájek R**. Atypická chronická myeloidní leukemie u nemocné po léčbě karcinomu prsu. *Onkol Revue* 2019;6(2):62-65.
3. **Zuchnická J**. Venetoklax – opakované použití u nemocné s prognosticky nepříznivou chronickou lymfocytární leukemií. *Acta medicae* 2019;11:132-135.
4. **Đuraš J**, **Hájek R**. Relabující lymfom z pláštových buněk léčený úspěšně ibrutinibem. *Acta medicae* 2019;11:123-124.

5. Bouwmeester, Walter; Briggs, Andrew; van Hout, Ben; **Hajek, Roman**; Gonzalez-McQuire, Sebastian; et al. Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. *Oncology And Therapy*. 2019 Dec;7(2):141-157.

### **Knihy a kapitoly v knihách**

1. **Kořístek Z, Jelínek T, Hájek R.** Vysokodávkovaná chemoterapie s transplantací krvetvorných buněk. In T. Büchler a kol. *Obecná onkologie*. Maxdorf Jessenius 2019, ISBN 978-80-7345-617-7.

### **Přednášky:**

#### **Přednášky (zahraniční konference)**

1. **Hájek R.** Translating Clinical Trial Results into Real-world Solutions. **2nd Annual Global Summit on Hematologic Malignancies**, Lisbon, 2/2019
2. **Hájek R.** Real-world considerations in the treatment of RRMM. Singapore and EM speaker tour. Singapur, 10/2019
3. **Hájek R.** Management of Challenging Cases. 17th International Myeloma Workshop. Boston, 9/2019
4. **Hájek R.** Co-chair Session: Antibody Based Approaches to MM. 17th International Myeloma Workshop. Boston, 9/2019
5. **Hájek R.** MM Real-World Data vs clinical trial. **Myeloma Real-World Data International Speaker Tour**. Shanghai, Tianjin, Jinan, 7/2019
6. **Hájek R.** The European Myeloma Network. **5th World Congress on Controversies in Multiple Myeloma**. Paříž, 5/2019
7. **Hájek R.** chair Session 11: Options for refractory myeloma. **5th World Congress on Controversies in Multiple Myeloma**. Paříž, 5/2019
8. **Hájek R.** Czech registry and utilization in clinical practice and health economic modeling. **MM Expert Panel**. Budapešť, 5/2019
9. **Hájek R.** Positioning of proteasome inhibitors in current ESMO Guidelines. **MM Expert Panel**. Budapešť, 5/2019
10. **Hájek R.** Unmet medical need in RRMM treatment. **Oncology Summit**. Vídeň, 4/2019
11. **Hájek R.** Multiple myeloma post SCT maintenance. **9th Annual SSBMT/EBMT 2019 Highlights congress**. Jeddah, 4/2019
12. **Hájek R.** Emerging Drugs and Targets. **7TH HEIDELBERG MYELOMA WORKSHOP**. Heidelberg, 4/2019
13. **Hájek R.** Real World Evidence in Multiple Myeloma. **Relapsed Refractory Multiple Myeloma AB**, Zurich, 3/2019
14. **Hájek R.** How I treat multiple myeloma in Central and Eastern Europe (CEE) using the newest drugs. **9th Current & Future Perspectives of MM Treatment and Other Hematological Malignancies Treatment Conference**, Varšava, 3/2019
15. **Hájek R.** Translating Clinical Trial Results into Real-world Solutions. **2nd Annual Global Summit on Hematologic Malignancies**, Lisbon, 2/2019

#### **Přednášky (tuzemská konference)**

1. **Ďuraš J.** Kazuistika - periferní T-lymfom. Plenární sjezd Kooperativní lymfomové skupiny 3/2019, Praha
2. **Popková T.** Cesta k AL amyloidóze. Pařízkovy dny, Ostrava 3/2019

3. **Plonková H.** Mnohočetný myelom – stále lépe léčitelné onemocnění. Pacientský seminář Ostrava, 5/2019
4. **Zuchnická J.** Vybrané kazuistiky. Seminář Trombocyty a POCT, 1/2019 Ostrava
5. **Gumulec J.** Soustředěná péče o pacienta s hemoragickými komplikacemi antikoagulační léčby. Dialog 2019, Valeč 4/2019
6. **Gumulec J.** Vyšetřování získaných a vrozených trombofilií. Pařízkovy dny, Ostrava 3/2019
7. **Gumulec J.** Trombotické mikroangiopatie u dospělých pacientů. Pařízkovy dny, Ostrava 3/2019
8. **Zuchnická J.** Lymfoproliferace - zajímavé klinické a morfologické nálezy. Dialog 2019, Valeč 4/2019
9. **Zuchnická J.** Chronická lymfocytární leukémie – známá neznámá. Regionální setkání pacientů s CML a CLL a jejich rodinných příslušníků, Ostrava 3/2019
10. **Zuchnická J.** Anémie v graviditě. Pařízkovy dny, Ostrava 3/2019
11. **Zuchnická J.** Ibrutinib u relabované CLL. Pařízkovy dny, Ostrava 3/2019
12. **Demel I.** Neobvyklá příčina získaného deficitu FVII: popis případu. Pařízkovy dny, Ostrava 3/2019
13. **Hájek R.** Novinky u MM. Pařízkovy dny, Ostrava 3/2019
14. **Bago J.** Cell therapy. Pařízkovy dny, Visegrad Symposium. Ostrava 3/2019.
15. **Bago J.** CAR-NK cells in cancer immunotherapy. Pařízkovy dny, Ostrava 3/2019
16. **Vdovin A.** OTUD1 as a new player in multiple myeloma pathogenesis. Pařízkovy dny, Ostrava 3/2019
17. **Bago J.** Cancer cell-based therapy. Life Science Faculty OU. Představení školitelů 2019/2020. Ostrava 11/2019
18. **Bago J.** Microfluidics in organoid systems. Medicinsky start-up inkubator III. Technická univerzita Ostrava. Ostrava 11/2019
19. **Bago J.** Induced neural stem cells for cancer therapy. XIV Multiple myeloma & II. Cell therapy workshop. Ostrava 10/2019
20. **Bago J.** Cell-based therapy: From Tissue Regeneration to Cancer Treatment. Life Science Faculty OU. Ostrava 3/2019

#### Postery:

##### Postery (zahraniční konference)

1. **Tereza Popkova, Katarina Hradská, Jana Mihalyova, Michaela Skorupova, Tomas Jelinek, Juraj Duras, Zdenek Koristek, Milan Navratil, Katerina Benkova, Hana Plonkova, Jana Zuchnicka, Jaromir Gumulec and Roman Hajek.** Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment. ASH, 12/2019
2. **Juli R. Bago.** INTRACEREBROVENTRICULAR DELIVERY OF TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELLS FOR TREATMENT OF BRAIN METASTASES. 24th Annual Meeting Society for NeuroOncology. Phoenix, USA. 11/2019.
3. **Juli R. Bago.** INCREASING INDUCED NEURAL STEM CELL PERSISTENCE IN THE TUMOR RESECTION CAVITY. 24th Annual Meeting Society for NeuroOncology. Phoenix, USA. 11/2019.
4. **Juli R. Bago.** NK CELL-BASED IMMUNOTHERAPY IN MULTIPLE MYELOMA. 4th International Symposium on Immunotherapy. London, UK. 5/2019.
5. **Vdovin A, Jelinek T, Hrdinka M, Bago JR, Sevcikova T, Hajek R et al.** Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib. 2019.
6. **Vdovin A, Jelinek T, Hrdinka M, Sevcikova T, Hajek R, Simicek M.** IDENTIFICATION OF NOVEL REGULATORS OF PLASMA CELLS MIGRATION IN MULTIPLE MYELOMA PATIENTS: PB2098. HemaSphere 2019; 3: 945.
7. **Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M et al.** QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION: PS1509. HemaSphere 2019; 3: 695–696.

8. Maisnar V, Pour L, Spicka I, Minarik J, Pavlicek P, **Jelinek T** et al. Registry of Monoclonal Gammopathies (RMG)-the monitored real-world database of the Czech Myeloma Group. *Clinical Lymphoma, Myeloma and Leukemia* 2019; 19: e324–e325.
9. Garces J, **Simicek M**, **Growkova K**, Calasanz M, Rios R, Martinez-Lopez J et al. THE TRANSCRIPTOMIC PROFILE OF THE CIRCULATING TUMOUR CELL (CTC) OF MULTIPLE MYELOMA: A NEW MODEL FOR UNDERSTANDING THE SPREAD OF THE DISEASE. FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY, 2019, pp 13–14.
10. Radocha J, **Jelinek T**, Pour L, Spicka I, Minarik J, Beranova K et al. Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule. *Clinical Lymphoma, Myeloma and Leukemia* 2019; 19: e180–e181.

### Postery (tuzemská konference)

1. **M. Turi**, S. Knapková, **D. Radhakrishnan**, **M. Simicek**, **M. Hrdinka**. UBIQUITINATION AS A POTENTIAL TARGET FOR NOVEL THERAPEUTIC APPROACHES IN MYD88-DRIVEN BLOOD CANCERS, Brno, 9/2019
2. **Popková T**, **Jelínek T**, **Plonková H**, **Szeligová L**, **Benková K**, **Kořístek Z**, **Zuchnická J**, **Navrátil M**, **Ďuraš J**, **Gumulec J**, **Growková K**, **Šimíček M**, **Hájek R**. První zkušenosti s venetoclaxem u pacientů s relabovaným/refrakterním mnohočetným myelomem. Pařížkovy dny, 3/2019
3. **Tereza Popkova**, **Michal Šimíček**, **Juli R. Bagó**, **Tomáš Jelínek**, Jiri Pergner, Serhiy Forostyak, **Kořístek Zdeněk**, **Roman Hájek**. NK-cell cancer immunotherapy. Pražský hematologický den 10/2019
4. **Juli R. Bago**. NK CELL-BASED IMMUNOTHERAPY IN MULTIPLE MYELOMA. XVII. národní workshop mnohočetný myelom a Roční setkání CMG. Mikulov, March, 2019.
5. Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, **Tomas Jelinek**, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, **Hana Plonkova**, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, **Lukas Stejskal**, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimír Maisnar, **Roman Hajek**. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of MonoclonalGammopathies (RMG). Pražský hematologický den 2019, Praha 9/2019
6. **Stejskal L**. OHD 2019 - Klinické registry CELL a současný pohled na sběr RWE dat. Olomouc 6/2019

### Abstrakta:

1. Pour, L; Efebera, YA; Granell, M; **Hajek, R**; Oriol, A; Delaunay, J; Le Du, K; Eveillard, JR; Karlin, L; Maisnar, V; Martinez-Lopez, J; Mateos, MV; Norkin, M; Ribrag, V; Richardson, PG; Straub, J; Byrne, C; Jacques, C; Sydvanter, M; Ocio, E. ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update. *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*, 19 S326-S327
2. San Miguel, J; Mateos, MV; Gonzalez, V; Dimopoulos, MA; Kastritis, E; **Hajek, R**; Rodriguez, CFD; Morgan, GJ; Merlini, G; Mangiacavalli, S; Goldschmidt, H; Cavo, M; Kyriakou, C; Qi, M; Ukropec, J; Weiss, BM; Cameron, C; Rajkumar, SV; Durie, BG; Kumar, S. Updated risk stratification model

- for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. JOURNAL OF CLINICAL ONCOLOGY, 37 (15):S MAY 20 2019
3. Sonneveld, P; Broijl, A; Gay, F; Boccadoro, M; Einsele, H; Blade, J; Dimopoulos, MA; Delforge, M; Spencer, A; **Hajek, R**; Schjesvold, F; Lonergan, S; Smith, E; Carson, RL; Crist, W; Garvin, WS; Vermeulen, J; Moreau, P. Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). JOURNAL OF CLINICAL ONCOLOGY, 37 (15):S MAY 20 2019
  4. Pour, L; Efebera, Y; Granell, M; **Hajek, R**; Oriol, A; Delaunay, J; Le Du, K; Eveillard, JR; Karlin, L; Maisnar, V; Martinez-Lopez, J; Mateos, MV; Moreb, J; Ribrag, V; Richardson, PG; Straub, J; Byrne, C; Jacques, C; Zubair, H; Ocio, E. Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104). CANCER RESEARCH, 79 (13):S 10.1158/1538-7445.AM2019-CT080 JUL 2019
  5. **Juli R. Bago**. Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib. 61st Annual Meeting American Society of Hematology. Orlando, USA. December 2019.
  6. **Juli R. Bago**. INTRACEREBROVENTRICULAR DELIVERY OF TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELLS FOR TREATMENT OF BRAIN METASTASES. 24th Annual Meeting Society for NeuroOncology. Phoenix, USA. November 2019.
  7. **Juli R. Bago**. INCREASING INDUCED NEURAL STEM CELL PERSISTENCE IN THE TUMOR RESECTION CAVITY. 24th Annual Meeting Society for NeuroOncology. Phoenix, USA. November 2019.
  8. **Juli R. Bago**. NK CELL-BASED IMMUNOTHERAPY IN MULTIPLE MYELOMA. 4th International Symposium on Immunotherapy. London, UK. May 2019.
  9. **Juli R. Bago**. Induced Neural Stem Cell Therapy to Treat Primary Triple Negative Breast Cancer. 22nd Annual Meeting American Society for Gene and Cell Therapy. Washington, USA. May 2019.
  10. **Juli R. Bago**. Therapeutic Induced Neural Stem Cells as a Treatment for Brain Metastases. 22nd Annual Meeting American Society for Gene and Cell Therapy. Washington, USA. May 2019.
  11. **Juli R. Bago**. Probing the Effects of Interpatient Variability on Autologous Engineered Neural Stem Cell Therapy for Glioblastoma. 22nd Annual Meeting American Society for Gene and Cell Therapy. Washington, USA. May 2019.
  12. Prochazka VK, Belada D, Janikova A, **Duras J** et al. Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals. Blood (2019) 134 (Supplement\_1): 3983. ASH 2019
  13. Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, **Plonkova H**, Štork M, Bacovsky J, Capkova L, Sykora M, Kessler P, **Stejskal L**, Heindorfer A, Ullrychová J, Maisnar V, **Hajek R**. Real-world comparison of ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. Volume 19, Issue 10, Supplement, October 2019, Pages e271–e272. Abstrakt IMW 2019, 17th International Myeloma Workshop Boston 9/2019
  14. Jakub Radocha, **Tomas Jelinek**, Ludek Pour, Ivan Spicka, Jiri Minarik, Katerina Beranova, **Hana Plonkova**, Alexandra Jungova, Petr Pavlicek, Lucie Brozova, Zdeněk Adam, Jan Straub, Jaroslav Bacovsky, Vladimir Maisnar, Tereza Dekojova, Adriana Heindorfer, Michal Sykora, Marek Wrobel, **Roman Hajek**. Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molekule. Clinical Lymphoma Myeloma and Leukemia. Volume 19, Issue 10, Supplement, October 2019, Pages e180-e181 Abstrakt IMW 2019, 17th International Myeloma Workshop Boston 9/2019
  15. **Stejskal L**. CML/ALL REAL LIFE DATA FINAL REPORT. ASH Orlando 12/201
  16. Garces, J. J.; **Simicek, M.**; **Growkova, K.**; **Jelínek R, Hájek R.** et al. THE TRANSCRIPTOMIC PROFILE OF THE CIRCULATING TUMOUR CELL (CTC) OF MULTIPLE MYELOMA: A NEW MODEL FOR UNDERSTANDING THE SPREAD OF THE DISEASE. 61st National Congress of the Spanish-Society-of-Hematology-and-Hemotherapy Location: Valencia, SPAIN Date: OCT 24-26, 2019.

HAEMATOLOGICA Volume: 104 Supplement: 3 Pages: 13-14 Meeting Abstract: CO-010 Published: OCT 21 2019

17. Pantani, L.; **Hajek, R.**; Gay, F.; et al. AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS BORTEZOMIB-MELPHALAN-PREDNISONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: FINAL ANALYSIS OF THE PHASE 3 EMN02/HO95 STUDY. 47th Congress of the Italian-Society-of-Hematology Location: Rome, ITALY Date: OCT 07-09, 2019. HAEMATOLOGICA Volume: 104 Supplement: 2 Pages: 49-49 Meeting Abstract: C087 Published: OCT 10 2019
18. Gkatzamanidou, Maria; Chyra, Zuzana; Shammash, Masood; **Hájek R.** et al. HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Issue: 10 Supplement: S Pages: E127-E128 Meeting Abstract: FP-126 Published: OCT 2019
19. Gregorova, Jana; Vrabel, David; Almasi, Martina; **Hájek R.** et al. Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Issue: 10 Supplement: S Pages: E177-E178 Meeting Abstract: FP-212 Published: OCT 2019
20. Kaiser, Martin; Beksac, Meral; Gulbrandsen, Nina; **Hajek R.** et al. Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Issue: 10 Supplement: S Pages: E293-E293 Meeting Abstract: SP-155 Published: OCT 2019
21. Maisnar, Vladimir; Pour, Ludek; Spicka, Ivan; **Jelínek T, Stejskal L, Hájek R.** et al. Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Issue: 10 Supplement: S Pages: E324-E325 Meeting Abstract: SP-207 Published: OCT 2019
22. Weisel, Katja; Hungria, Vania; Leleu, Xavier; **Hájek R.** et al. A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Issue: 10 Supplement: S Pages: E4-E5 Meeting Abstract: OAB-005 Published: OCT 2019
23. Pour, Ludek; Efebera, Yvonne A.; Granell, Miquel; **Hajek R.** et al. ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 19 Supplement: 1 Pages: S326-S327 Meeting Abstract: MM-168 Published: SEP 2019
24. Pour, Ludek; Efebera, Yvonne; Granell, Miquel; **Hajek R.** et al. Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104) Conference: Annual Meeting of the American-Association-for-Cancer-Research (AACR) Location: Atlanta, GA Date: MAR 29-APR 03, CANCER RESEARCH Volume: 79 Issue: 13 Supplement: S Meeting Abstract: CT080 Published: JUL 2019
25. Cook, G.; **Hajek, R.**; Terpos, E.; et al. Ixazomib plus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies. Conference: 59th Annual Scientific Meeting of the British-Society-for-Hematology Location: Glasgow, SCOTLAND Date: APR 01-03, 2019. BRITISH JOURNAL OF HAEMATOLOGY Volume: 185 Special Issue: SI Supplement: 1 Pages: 16-17 Meeting Abstract: BSH19-OR-0 Published: MAR 2019
26. Kaiser, M.; Dimopoulos, M. A.; Gay, F.; **Hajek R.** et al. Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial. Group Author(s): TOURMALINE MM3 Study Grp Conference: 59th Annual Scientific Meeting of the British-Society-for-Hematology Location: Glasgow, SCOTLAND Date: APR 01-03, 2019. BRITISH JOURNAL OF HAEMATOLOGY Volume: 185 Special Issue: SI Supplement: 1 Pages: 18-19 Meeting Abstract: BSH19-OR-0 Published: MAR 2019
27. **Gumulec, J.**; Simetka, O.; Kasprak, D.; **Navrátil M, Kořístek Z, Hájek R.** et al. Comprehensive care improves the prognosis of women with severe HELLP syndrome and postpartal thrombotic



- microangiopathic syndrome. Conference: 8th International Symposium on Women's Health Issues in Thrombosis and Haemostasis Location: Madrid, SPAIN Date: MAR 29-31, 2019. THROMBOSIS RESEARCH Volume: 175 Supplement: 1 Pages: S15-S15 Meeting Abstract: P025 Published: MAR 2019
28. **J. Ďuraš**, V. Procházka, D. Belada, A. Janíková, H. Móciková, K. Kopečková, **R. Hájek**, M. Trněný. PREDICTIVE VALUE OF PRIMA-PROGNOSTIC INDEX (PRIMA-PI) IN FIRST RELAPSE OF FOLLICULAR LYMPHOMA. *Hematological Oncology*. 2019;37(S2):398-399 IF 3,439
  29. Jacobsen E, **Ďuraš J**, Ardesna K, et al. Characterization of Duvelisib in Patients with Refractory Marginal Zone Lymphoma: Data from the Phase 2 Dynamo Trial. *Hematological Oncology*. 2019;37(S2):400–401. IF 3,439
  30. Šimkovič M, Móciková H, **Duras J** et al. DA-EPOCH-R VERSUS R-CHOP IN HIGH RISK DLBCL PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP (CLSG). *Hematological Oncology*. 2019;37(S2):433-434. IF 3,439
  31. Trneny M, Polgarova K, Janikova A, D. Belada, V. Prochazka, **J. Duras**, et al. IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY? *Hematological Oncology*. 2019;37(S2):267–268. IF 3,439
  32. A. Janikova, R. Chloupkova, V. Campr, N. Kopalova, P. Klener, K. Benesova, J. Hamouzova, D. Belada, A. Sykorova, V. Prochazka, J. Pirnos, J. **Duras**, H. Mocikova, J. Michalka. M. Trneny. PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE. *Hematological Oncology*. 2019;37(S2):413–414. IF 3,439
  33. A. Janikova, R. Chloupkova, P. Klener, K. Benesova, D. Belada, A. Sykorova, V. Prochazka, N. Kopalova, J. Hamouzova, J. Pirnos, **J. Duras**, H. Mocikova, M. Trneny. T-CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY? *Hematological Oncology*. 2019;37(S2):465–467. IF 3,439
  34. Pour Ludek; Efebera, Yvonne; A. Granell, Miquel; et al. Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104). *AMERICAN JOURNAL OF HEMATOLOGY*. *AMERICAN JOURNAL OF HEMATOLOGY* Volume: 94 Special Issue: SI Supplement: 2 Pages: S23-S24 Meeting Abstract: P-034 Published: NOV 2019